Publicaciones en colaboración con investigadores/as de University of Toronto (26)

2022

  1. Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis

    Therapeutic Advances in Medical Oncology, Vol. 14

2020

  1. HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates

    Breast Cancer Research, Vol. 22, Núm. 1

  2. Integrin ανβ6 Protein Expression and Prognosis in Solid Tumors: A Meta-Analysis

    Molecular Diagnosis and Therapy, Vol. 24, Núm. 2, pp. 143-151

2019

  1. Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome

    OncoImmunology, Vol. 8, Núm. 10

  2. Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors

    PLoS ONE, Vol. 14, Núm. 4

  3. Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis

    Frontiers in Oncology, Vol. 9

2018

  1. Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: Understanding clinical trial results

    Oncotarget, Vol. 9, Núm. 61, pp. 31915-31919

  2. Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer

    Breast Cancer Research and Treatment, Vol. 172, Núm. 3, pp. 725-732

  3. Functional transcriptomic annotation and protein–protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer

    Cancer Medicine, Vol. 7, Núm. 5, pp. 1896-1907

2017

  1. Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer Drugs

    Molecular Diagnosis and Therapy, Vol. 21, Núm. 3, pp. 337-343

  2. Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors

    Oncotarget, Vol. 8, Núm. 13, pp. 21733-21740

  3. Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumors

    PLoS ONE, Vol. 12, Núm. 5

  4. Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers

    Scientific Reports, Vol. 7, Núm. 1

2016

  1. Circulating DNA and survival in solid tumors

    Cancer Epidemiology Biomarkers and Prevention, Vol. 25, Núm. 2, pp. 399-406

  2. In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: Role of mitotic kinases

    Oncotarget, Vol. 7, Núm. 16, pp. 22865-22872

  3. Neuregulin expression in solid tumors: Prognostic value and predictive role to anti-HER3 therapies

    Oncotarget, Vol. 7, Núm. 29, pp. 45042-45051

  4. Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancer

    Breast Cancer Research and Treatment, Vol. 156, Núm. 1

2015

  1. Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer

    Oncotarget, Vol. 6, Núm. 29, pp. 27923-27937

  2. Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: Systematic review and meta-analyses

    Oncotarget, Vol. 6, Núm. 37, pp. 39538-39549

  3. Tumor-Infiltrating lymphocytes in breast cancer: Ready for prime time?

    Journal of Clinical Oncology